|
Gene: HUWE1 |
Gene summary for HUWE1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HUWE1 | Gene ID | 10075 |
Gene name | HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1 | |
Gene Alias | ARF-BP1 | |
Cytomap | Xp11.22 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | A0A024R9W5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10075 | HUWE1 | CA_HPV_1 | Human | Cervix | CC | 3.05e-02 | -4.49e-02 | 0.0264 |
10075 | HUWE1 | CCI_1 | Human | Cervix | CC | 5.39e-05 | 6.43e-01 | 0.528 |
10075 | HUWE1 | CCI_2 | Human | Cervix | CC | 1.97e-07 | 9.88e-01 | 0.5249 |
10075 | HUWE1 | CCI_3 | Human | Cervix | CC | 8.46e-04 | 6.21e-01 | 0.516 |
10075 | HUWE1 | AEH-subject1 | Human | Endometrium | AEH | 9.45e-10 | 3.77e-01 | -0.3059 |
10075 | HUWE1 | AEH-subject2 | Human | Endometrium | AEH | 3.06e-06 | 2.41e-01 | -0.2525 |
10075 | HUWE1 | AEH-subject3 | Human | Endometrium | AEH | 1.79e-06 | 2.69e-01 | -0.2576 |
10075 | HUWE1 | AEH-subject4 | Human | Endometrium | AEH | 1.45e-08 | 3.79e-01 | -0.2657 |
10075 | HUWE1 | AEH-subject5 | Human | Endometrium | AEH | 4.23e-04 | 3.97e-01 | -0.2953 |
10075 | HUWE1 | EEC-subject1 | Human | Endometrium | EEC | 5.26e-13 | 4.17e-01 | -0.2682 |
10075 | HUWE1 | EEC-subject3 | Human | Endometrium | EEC | 6.79e-10 | 1.91e-01 | -0.2525 |
10075 | HUWE1 | EEC-subject4 | Human | Endometrium | EEC | 6.23e-03 | 2.14e-01 | -0.2571 |
10075 | HUWE1 | EEC-subject5 | Human | Endometrium | EEC | 1.77e-07 | 3.24e-01 | -0.249 |
10075 | HUWE1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.39e-17 | 1.50e-01 | -0.1869 |
10075 | HUWE1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.09e-12 | -4.05e-03 | -0.1875 |
10075 | HUWE1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.65e-15 | 7.22e-02 | -0.1883 |
10075 | HUWE1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.03e-08 | 8.68e-02 | -0.1934 |
10075 | HUWE1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.71e-19 | 9.55e-02 | -0.1917 |
10075 | HUWE1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 3.97e-18 | 1.42e-01 | -0.1916 |
10075 | HUWE1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 3.59e-03 | 2.22e-01 | -0.1269 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
GO:00705859 | Cervix | CC | protein localization to mitochondrion | 33/2311 | 125/18723 | 1.46e-05 | 2.90e-04 | 33 |
GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412021 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
hsa0412031 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0412012 | Lung | IAC | Ubiquitin mediated proteolysis | 40/1053 | 142/8465 | 3.24e-07 | 1.76e-05 | 1.17e-05 | 40 |
hsa0412013 | Lung | IAC | Ubiquitin mediated proteolysis | 40/1053 | 142/8465 | 3.24e-07 | 1.76e-05 | 1.17e-05 | 40 |
hsa0412022 | Lung | AIS | Ubiquitin mediated proteolysis | 41/961 | 142/8465 | 8.01e-09 | 4.33e-07 | 2.77e-07 | 41 |
hsa0412032 | Lung | AIS | Ubiquitin mediated proteolysis | 41/961 | 142/8465 | 8.01e-09 | 4.33e-07 | 2.77e-07 | 41 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HUWE1 | SNV | Missense_Mutation | c.8069G>T | p.Arg2690Leu | p.R2690L | Q7Z6Z7 | protein_coding | deleterious(0) | benign(0.17) | TCGA-35-4122-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HUWE1 | SNV | Missense_Mutation | c.8366N>G | p.Ser2789Cys | p.S2789C | Q7Z6Z7 | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-44-2655-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
HUWE1 | SNV | Missense_Mutation | c.7903N>T | p.Thr2635Ser | p.T2635S | Q7Z6Z7 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-44-3917-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HUWE1 | SNV | Missense_Mutation | c.6641G>T | p.Arg2214Leu | p.R2214L | Q7Z6Z7 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-44-7667-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HUWE1 | SNV | Missense_Mutation | c.8930N>A | p.Pro2977His | p.P2977H | Q7Z6Z7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-49-4488-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
HUWE1 | SNV | Missense_Mutation | c.2372N>T | p.Gln791Leu | p.Q791L | Q7Z6Z7 | protein_coding | deleterious(0.03) | benign(0.023) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
HUWE1 | SNV | Missense_Mutation | novel | c.8708N>A | p.Arg2903Lys | p.R2903K | Q7Z6Z7 | protein_coding | tolerated_low_confidence(0.92) | benign(0.001) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
HUWE1 | SNV | Missense_Mutation | novel | c.1975N>G | p.Leu659Val | p.L659V | Q7Z6Z7 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
HUWE1 | SNV | Missense_Mutation | c.2191G>A | p.Glu731Lys | p.E731K | Q7Z6Z7 | protein_coding | tolerated(0.08) | possibly_damaging(0.908) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HUWE1 | SNV | Missense_Mutation | c.6937G>T | p.Val2313Leu | p.V2313L | Q7Z6Z7 | protein_coding | tolerated(0.25) | benign(0.018) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |